Greenwich Lifesciences Inc (GLSI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $201.97M
Last updated: Nov 17, 2026 at 4:41 PM ET
Greenwich Lifesciences Inc (GLSI) Statistics
Greenwich Lifesciences (GLSI) has a market cap of $201.97M and an enterprise value of $196.07M. Its share count is up 7.60% from a year earlier.
Total Valuation
Enterprise value is 2.92% below the market cap, as cash exceeds debt.
| Market Cap | $201.97M |
|---|---|
| Enterprise Value | $196.07M |
| Latest price (Nov 17, 2026) | $18.70 |
Key Dates
The next earnings report is expected on Jun 2, 2027, covering the quarter ending Mar 31, 2027.
| Next Earnings Date | Jun 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 11, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 124.76% over 52 weeks and trades 12.79% above its 50-day average.
| Beta (1Y) | 3.12 |
|---|---|
| 52-Week Change | +124.76% |
| 1-Month Change | +22.95% |
| 3-Month Change | +7.84% |
| 6-Month Change | -28.92% |
| 5-Year Change | -50.76% |
| Total Return (1Y) | +124.76% |
| Total Return (3Y CAGR) | +20.41% |
| Total Return (5Y CAGR) | -11.84% |
| Return vs SPY (1Y) | +115.38% |
| Max Drawdown (1Y) | -61.87% |
| Max Drawdown (3Y) | -61.87% |
| Sharpe Ratio (1Y) | 0.75 |
| Correlation with SPY (1Y) | 0.39 |
| 50-Day Average | $16.58 |
| 200-Day Average | $20.84 |
| 52-Week Range | $7.78 to $34.10 |
| RSI (14 Days) | 59.0 |
| Average Volume (20 Days) | 179.59K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.77x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.77x |
|---|---|
| Quick Ratio | 0.77x |
| Debt / Equity | 0.00x |
Scores
GLSI has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$23.55M |
| Pretax Income | -$23.34M |
| Net Income | -$23.34M |
| Reported EPS (TTM) | -$1.54 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $5.90M |
|---|---|
| Total Debt | $0 |
| Net Cash | $5.90M |
| Net Cash Per Share | $0.40 |
| Working Capital | -$1.75M |
| Shareholder Equity | -$1.75M |
| Total Assets | $5.90M |
| Total Liabilities | $7.65M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$12.79M |
|---|---|
| FCF Per Share | -$0.87 |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -78.24% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -78.23% |
Dividends and Yields
GLSI does not pay a dividend.
| Buyback Yield | -5.42% |
|---|---|
| Shareholder Yield | -5.42% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About GLSI
What is GLSI's market cap?
Greenwich Lifesciences has a market cap of $201.97M. Its enterprise value, which adds debt and subtracts cash, is $196.07M.
How many shares of GLSI are outstanding?
Greenwich Lifesciences has 14.68M shares outstanding. The count is up 7.60% from a year earlier.
Does GLSI pay a dividend?
No. Greenwich Lifesciences does not pay a dividend.
How much debt does GLSI have?
Greenwich Lifesciences has $0 of total debt and $5.90M of cash and equivalents, a net cash position of $5.90M.
GLSI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors